RBC Capital raised the firm’s price target on Boston Scientific to $78 from $70 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 earnings for Medical Devices. The sector fundamentals are “flashing positive signals” and the firm is expecting strong results, the analyst tells investors in a research note. RBC adds that its checks continue to be notably positive on PFA adoption and shift from RF/Cryo, the pace of ramp, the company’s market share and pull through to the rest of the portfolio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $80 from $69 at Argus
- Boston Scientific price target raised to $79 from $71 at Citi
- Piper says competitive process could materialize for ShockWave
- Boston Scientific, Scivita Medical expand strategic cooperation arrangement
- Axonics shareholders approve merger with Boston Scientific